Additional file 3: Figure S1. of Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study

  • Michael J. Sadowsky (Contributor)
  • Thomas Borody (Contributor)
  • J.Gregory Caporaso (Northern Arizona University) (Contributor)
  • Rosa Krajmalnik-Brown (Contributor)
  • Elizabeth Geis (Contributor)
  • Alexander Khoruts (Contributor)
  • Elena L. Pollard (Contributor)
  • Matthew B. Sullivan (Contributor)
  • Dae Wook Kang (Contributor)
  • Sharon McDonough-Means (Contributor)
  • Karen Schwarzberg Lipson (Contributor)
  • Simon Roux (Contributor)
  • Ann C. Gregory (Contributor)
  • Alessio Fasano (Contributor)
  • James B. Adams (Contributor)
  • Juan Maldonado (Contributor)
  • Lauren Chittick (Contributor)



Subscores of GI- and ASD-related symptoms in 18 children with ASD. Figure S2. Correlation between percentage change in GSRS and overall PGI-III scores (based on the data shown in Fig. 2a, b) for the 18 weeks of the study. Figure S3. Vineland developmental age (in years) for individual subscales and for the average of all subscales, measured at baseline and at the end of observation 4 months later. Figure S4. Stool microbiota changes in community richness with fecal microbiota transplant. Figure S5. Gut phageome taxonomy is still mostly unknown. Figure S6. Subscores of the PGI-III at end of treatment (week 10). Figure S7. Microbiota changes with fecal microbiota transplant based on swab samples (analog of Fig 3a–d). Figure S8. Stool microbiota changes with fecal microbiota transplant. Figure S9. Engraftment plots with four diversity metrics (stool samples). Figure S10. Stool microbiota changes with fecal microbiota transplant. (PDF 1964 kb)
Date made availableJan 1 2017
Publisherfigshare Academic Research System

Cite this